作为乳腺癌低克劳丁亚型的潜在目标的MRCK
Hirohito Yamaguchi1,2,3, Ling-Chu Chang2,3, Olin Shih-Shin Chang4,5
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung City 406040, Taiwan R.O.C.
International journal of biological sciences
|January 2, 2024
概括
像BDP-9066这样的MRCK抑制剂显示出作为治疗三阴性乳腺癌 (TNBC) 的新药的前景. 这项研究强调了它们的有效性,特别是在低克劳丁亚型中,通过准YAP/TAZ途径.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 三阴性乳腺癌 (TNBC) 缺乏向疗法.
- 识别新的分子标对于有效的TNBC治疗至关重要.
研究的目的:
- 为了确定TNBC的新药候选者.
- 阐明MRCK抑制剂在TNBC中的作用机制.
主要方法:
- 乳腺癌亚型的大规模药物查分析.
- 在体外和体内验证BDP-9066的疗效和特异性.
- 敏感细胞和耐药细胞的转录学比较.
- 对YAP/TAZ,NF-κB和PI3K通路参与的分析.
主要成果:
- BDP-9066,一种特定的MRCK抑制剂 (MRCKi),已证明对TNBC的有效性.
- 在敏感细胞中被认为是关键的焦点粘附和YAP/TAZ通路的激活.
- BDP-9066抑制了YAP/TAZ,而活性YAP/TAZ则抑制了BDP-9066的作用.
- 在TNBC中,YAP/TAZ和焦粘附基因的表达高,特别是Claudin-low亚型.
- NF-κB作用于YAP/TAZ的下游,并被BDP-9066.6抑制.
- 使用alpelisib抑制PI3K通路,在PIK3CA突变TNBC细胞中协同增强了BDP-9066的影响.
结论:
- MRCK 抑制剂代表了对TNBC的新型药物,特别是低克劳丁亚型.
- 准YAP/TAZ通路是TNBC治疗的一个有希望的策略.
- 与PI3K抑制剂的联合治疗可能会提高特定TNBC亚型的疗效.
更多相关视频
11:12Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.0K
07:13Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
Published on: March 26, 2014
23.4K
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
